Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has a confirmed diagnosis of endogenous Cushing's syndrome.~2. Requires medical treatment of hypercortisolemia.~3. Meets at least one of the following criteria:~   1. Has type 2 diabetes mellitus.~  2. Has impaired glucose tolerance.~  3. Has hypertension.~Exclusion Criteria:~1. Has non-endogenous source of hypercortisolemia~2. Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism~3. Has poorly controlled hypertension~4. Has Stage ≥ 4 renal failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: Low-dose Group (Type: EXPERIMENTAL): 100 mg/day for 4 weeks in Period 1, then 150 mg/day for 4 weeks in Period 2, then 200 mg/day for 4 weeks in Period 3. There was no washout between treatment periods. Period 3 was followed by a 4-week follow-up period. Per-protocol, Group 1 did not participate in treatment Period 4.
- Group 2: High-dose Group (Type: EXPERIMENTAL): 250 mg/day for 4 weeks in Period 1, then 300 mg/day for 4 weeks in Period 2, then 350 mg/day for 4 weeks in Period 3, then 400 mg/day for 4 weeks in Period 4. There was no washout between treatment periods. Period 4 was followed by a 4-week follow-up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).